logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5569.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5569.produseast1
Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era

Beckert P, Sanchez-Padilla E, Merker M, Dreyer V, Kohl TA,  et al.
2020-11-25 • Genome Medicine
2020-11-25 • Genome Medicine
Background
Multidrug-resistant (MDR) Mycobacterium tuberculosis complex strains not detected by commercial molecular drug susceptibility testing (mDST) assays due to the RpoB I491F ...
Journal Article
|
Research

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Ismail N, Omar SV, Moultrie H, Bhyat Z, Conradie F,  et al.
2021-11-12 • Lancet Infectious Diseases
2021-11-12 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...
Journal Article
|
Research

Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?

Ndjeka N, Hughes J, Reuter A, Conradie F, Enwerem M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for t...
Journal Article
|
Research

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen

Ndjeka N, Schnippel K, Master I, Meintjes GA, Maartens G,  et al.
2018-10-25 • European Respiratory Journal
2018-10-25 • European Respiratory Journal
Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a ...
Journal Article
|
Research

Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study

Schnippel K, Ndjeka N, Maartens G, Meintjes GA, Master I,  et al.
2018-09-01 • Lancet Respiratory Medicine
2018-09-01 • Lancet Respiratory Medicine
Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Foll...
Journal Article
|
Letter

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?

Ndjeka N, Conradie F, Meintjes GA, Reuter A, Hughes J,  et al.
2020-07-23 • European Respiratory Journal
2020-07-23 • European Respiratory Journal
Rapid adoption of new diagnostic tools, parallel process of research and implementation, decentralisation of services, the use of personal protective equipment, as well as strong partner...